Abstract:BACKGROUND: Sirolimus is a new generation of immunosuppressive agent with little renal toxicity, as well as effects of anti-proliferation and anti-tumor, which can decrease the occurrence of adverse reaction such as hepatic and renal toxicity, as well as serious infection in renal transplant recipients. OBJECTIVE: To verify the efficacy and safety of conversion treatment with sirolimus in renal transplant recipients using the calcineurin inhibitor (CNI) with one or more risk factors. DESIGN, TIME AND SETTING: A retrospective analysis on cases was performed in the Research Institute of Nephrology, Nanjing General Hospital of Nanjing Military Command from June 2003 to December 2006. PARTICIPANTS: A total of 93 patients performed conversion treatment with sirolimus after renal transplantation. They consisted of 59 males and 34 females, with an average age of (38.2±11.1) years. Among them, CNI induced renal toxicity were in 13 (13.9%) cases, CNI induced hepatic toxicity were in 26 (28.0%) cases, post-transplantation diabetes mellitus were in 11 (11.8%) cases, chronic allograft nephropathy were in 33 (35.5%) cases, and post-transplantation tumor were in 10 (10.8%) cases. METHODS: Rapid conversion with sirolimus was performed in all patients. The CNI withdrawal was in 2 weeks. At 4 hours after oral administration of cyclosporin A or Tacrolimus, the patients took sirolimus. Initial dose of sirolimus was 6 mg, and repeated maintenance dose is 1.0-2.0 mg/d. The first concentration of sirolimus was detected at 5-7 days after first oral administration, and the target concentration was 6-10 μg/L. MAIN OUTCOME MEASURES: Serum creatinine levels, incidence of acute rejection, loss rate of grafts, pulmonary infection, and mortality rates were dynamically observed after conversion with sirolimus. RESULTS: The symptoms were markedly improved in patients with CNI induced renal toxicity and CNI induced liver toxicity, and the concentration of sirolimus were maintained at (5.1±1.2) μg/L. Serum creatinine levels decreased from (297.72±150.28) μmol/L to (123.76±44.2) μmol/L, and the liver function were recovery in 24 (92.3%) patients. 9 patients with high glucose returned to normal, and 2 patients were improved. Serum creatinine levels decreased more than 25% of primary level in 17 patients, and the effective rate was 51.5%. 10 patients with tumor were appeared 6-43 months after renal transplantation, no recurrence was found in 8 of them and 2 patients were dead. Acute rejections were occurred in 3 patients at 6 months after conversion treatment. The complications were included hyperlipidemia and proteinuria. 3 patients were dead, 6 patients returned to dialysis treatment, and 2 patients were removal of grafts. At 3 years after conversion treatment, the survival rates of patients and grafts were 90.9% and 75.8%, respectively. CONCLUSION: The conversion treatment with SRL and MMF may be a better option for the renal transplant recipients using the CNI with risk factors appeared.

Clinical Effect of Conversion to Rapamycin on Chronic Allograft Nephropathy

[Conversion to Rapamycin in Liver Transpant Recipients with Renal Insufficiency].

Conversion from Calcineurin Inhibitors to Sirolimus in Chronic Allograft Nephropathy: a 4-Year Prospective Study

Effect of conversion from calcineurin inhibitor to sirolimus on chronic allograft nephropathy

Observation of Efficacy and Safety of Converting the Calcineurin Inhibitor to Sirolimus in Renal Transplant Recipients with Chronic Allograft Nephropathy

[Early Conversion from Calcineurin Inhibitor to Sirolimusto after Renal Transplantation:A Prospective, Open-Label and Non-Randomized Control Study].

Five-year Follow-Up after Conversion from Calcineurin Inhibitor to Sirolimus-Based Treatment in Kidney Transplant Patients with Chronic Allograft Nephropathy.

Conversion from calcineurin inhibitor to sirolimus for renal function deterioration in kidney allograft recipients

Conversion from cyclosporine to sirolimus in chronic renal allograft dysfunction: a 4-year prospective study.

Protective Effects of Sirolimus by Attenuating Connective Tissue Growth Factor Expression in Human Chronic Allograft Nephropathy.

Safety and efficacy of conversion from calcineurin inhibitors to mammalian-target-of-rapamycin inhibitors in liver transplant recipients: a meta-analysis of randomized controlled trials

Conversion From Calcineurin Inhibitors to Mammalian Target of Rapamycin Inhibitors in Kidney Transplant Recipients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Efficacy of the Program of Rapamycin Combined with CNI in Chronic Allograft Nephropathy

Conversion treatment With Sirolimus in renal transplant recipients

Combined Regimen of Rapamycin and Ciclosporin in Long-Term Follow-Up in Renal Allograft Recipients

Clinical investigation on abrupt conversion of low-dose sirolimus after kidney transplantation

Evaluation of Conversion Treatment with SRL in Organ Transplant Recipients

Long-term outcomes in rapamycin on renal allograft function: a 30-year follow-up from a single-center experience

A randomized controlled trial to evaluate efficacy and safety of early conversion to a low-dose calcineurin inhibitor combined with sirolimus in renal transplant patients

A multi-center randomized controlled trial to evaluate efficacy and safety of early conversion to a low-dose calcineurin inhibitor combined with sirolimus in renal transplant patients

Conversion from Calcineurin Inhibitors to Mammalian Target-of-Rapamycin Inhibitors in Heart Transplant Recipients: A Meta-Analysis of Randomized Controlled Trials.